Special Issue

Next-Generation Targeted Therapy: vNARs as Drug Carriers and Intracellular Neutralizing Agents

Message from the Guest Editors

vNAR single-domain antibodies, originally isolated from sharks, have emerged as a revolutionary tool for drug carriers and intracellular neutralizing agents for human diseases.vNARs are a small natural antibody domain with antigen recognition capacity and unique features. such as compact size (approximately 12-15 kDa), exceptional thermal and chemical stability, high affinity, high solubility, and access to cryptic epitopes. These remarkable characteristics suggest that vNAR application may be suitable for drug delivery and intracellular neutralization, offering unparalleled opportunities across diverse scientific disciplines. including nanotechnology, biomedicine, drug delivery, biosensing, intrabodies, payload, and imaging. This Special Issue aims to unlock the full therapeutic and diagnostic power of vNAR single-domain antibodies, ultimately benefiting global health and advancing biomedical science.

Guest Editors

Dr. Tanya Camacho-Villegas

Unidad de Biotecnología Médica y Farmacéutica, Centro de Investigación y Asistencia en Tecnología y Diseño del Estado de Jalisco (CIATEJ), Guadalajara C.P. 44270, Jalisco, Mexico

Dr. Mirna Burciaga-Flores

Centro de Nanociencias y Nanotecnología, Universidad Nacional Autónoma de México (CNyN-UNAM), Carretera Tijuana-Ensenada km107, Ensenada C.P. 22860, Baja California, Mexico

Deadline for manuscript submissions

28 November 2025



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



mdpi.com/si/243297

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





Pharmaceutica

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals*.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

